Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
UPDATE: Cantor Fitzgerald Starts Lyra Therapeutics (LYRA) at Overweight
-
Form 13F-NT/A Cantor Fitzgerald Europe For: Mar 31
-
Form 13F-NT/A CANTOR FITZGERALD & CO. For: Mar 31
-
Form 13F-NT/A CANTOR FITZGERALD SECURI For: Mar 31
-
Form 13F-HR/A CANTOR FITZGERALD, L. For: Mar 31
-
"Approval of Tyvaso DPI Marks Significant Inflection Point", Shares Present "Upside From Current Levels" - Cantor Fitzgerald Bullish on MannKind (MNKD) with $6.50 Price Target
-
Sanara MedTech (SMTI) PT Lowered to $40 at Cantor Fitzgerald, Overweight Rating Maintained
-
Near to go Public on Nasdaq via Merger with KludeIn I Acquisition Corp. (INKA)
-
Near, a Global Leader in Privacy-Led Data Intelligence, to go Public on Nasdaq via a Merger with KludeIn I Acquisition Corp.
-
/C O R R E C T I O N -- Near North America, Inc./
-
Data intelligence firm Near to go public via $1 billion SPAC deal
-
Investors jolted as U.S. retailers show inflation hitting consumers
-
Investors jolted as U.S. retailers show inflation hitting consumers
-
Investors jolted as U.S. retailers show inflation hitting consumers
-
Form 4 BGC Partners, Inc. For: May 17 Filed by: CANTOR FITZGERALD, L. P.
-
Cantor Fitzgerald Reiterates Overweight Rating, $53 Price Target on Insmed (INSM)
-
Form 4 NEWMARK GROUP, INC. For: May 17 Filed by: CANTOR FITZGERALD, L. P.
-
Allakos Inc. (ALLK) PT Lowered to $10 at Cantor Fitzgerald, But BUY Rating Maintained, "Still Believe that the Market Opportunity for lirentelimab is Underappreciated"
-
Cantor Fitzgerald Reiterates Overweight Rating, $7 Price Target on VolitionRX (VNRX), Has a "More Favorable View of the Company"
-
Cantor Fitzgerald Reiterates Overweight Rating, $19 Price Target on Exagen (XGN) on Alivio Health Agreement
-
Form SC 13D/A Satellogic Inc. Filed by: CANTOR FITZGERALD, L. P.
-
Form 424B3 Cantor Fitzgerald Income
-
Enigma Securities Appoints Barry Finkelstein as Global Head of Investment Banking
-
Appreciate to Go Public Via Merger with PropTech Investment Corporation II (PTICU)
-
PropTech Investment Corporation II to Combine with Appreciate, Bringing Single Family Rental Marketplace & Management Platform, Renters Warehouse, to the Public Markets
-
PropTech Investment Corporation II to Combine with Appreciate, Bringing Single Family Rental Marketplace & Management Platform, Renters Warehouse, to the Public Markets
-
Cantor Fitzgerald Reiterates Neutral Rating on TherapeuticsMD (TXMD)
-
UPDATE: Aytu Biosciences (AYTU) PT Lowered to $5 at Cantor Fitzgerald, "Overweight" Rating Reiterated, Analyst Expects "Upwards Earnings Revisions Should Drive Shares Higher"
-
Spero Therapeutics (SPRO) PT Slashed to $5 at Cantor Fitzgerald, Analyst Maintains "Overweight" Rating
-
Form 13F-NT CANTOR FITZGERALD & CO. For: Mar 31
-
Form 13F-HR CANTOR FITZGERALD, L. For: Mar 31
-
Form 13F-NT CANTOR FITZGERALD SECURI For: Mar 31
-
Form 13F-NT Cantor Fitzgerald Europe For: Mar 31
-
Form 10-Q Cantor Fitzgerald Income For: Mar 31
-
Form SC 13G Cartesian Growth Corp Filed by: CANTOR FITZGERALD SECURITIES
-
Cantor Fitzgerald Reiterates Overweight Rating. $15 Price Target on ContraFect (CFRX), "Expect Upwards Earnings Revision to Move Share Higher"
-
Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights
-
Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights
-
UPDATE: Benchmark Downgrades Shift Technologies Inc. (SFT) to Hold
-
Lionheart Acquisition Corporation II (LCAPU) Enters Non-Binding Term Sheets for Forward Purchase Agreement and Committed Equity Facility with Cantor Fitzgerald
-
Lionheart Acquisition Corporation II Enters into Non-Binding Term Sheets for Forward Purchase Agreement and Committed Equity Facility with Cantor Fitzgerald L.P.
-
Cantor Fitzgerald Assumes Poseida Therapeutics, Inc (PSTX) at Overweight
-
Cantor Fitzgerald Assumes Harpoon Therapeutics (HARP) at Overweight
-
CF Acquisition Corp. VI (CFVI) and Rumble File Amended Registration Statement for Proposed Merger
-
CF Acquisition Corp. VI and Rumble Announce Filing of Amended Registration Statement in Connection with their Proposed Business Combination
-
Cantor Fitzgerald Reiterates VYNE Therapeutics (VYNE) at Overweight with $10 Price Target, Expects "Upwards Earnings Estimate Revisions and Multiple Expansion"
-
Cantor Fitzgerald Reiterates Overweight Rating on Fortress Biotech (FBIO) on Q1 Report, "Risk-Diversification Remains Attractive "
-
Cantor Fitzgerald Reiterates Overweight Rating on Checkpoint Therapeutics (CKPT) on Q1 Report
-
Cantor Fitzgerald Reiterates Overweight Rating, $5 on PAVmed (PAVM), "Encourage Investors to Acquire PAVM Shares at Attractive Valuation"
-
BancTrust & Co. Investment Bank Announces Launch of U.S. Broker-Dealer Affiliate

